2022-09-30-accounts - Orchid Cancer Appeal

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

Fighting male cancer

Orchid Cancer Appeal Annual report and nancial statements fi 2021-2022

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Orchid Cancer Appeal Annual report and nancial statements fi 2021-2022

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Board of Trustees

Mr CS Osborne Chair Mr W Cohen Treasurer Mr D Badenoch Mr PG Bracher Mr S Harris Mr M Kibblewhite Professor RTD Oliver Mr P Norman Mr S Seymour (resigned 1 January 2022) Mr N Watkin (resigned 7 December 2021) Mr B Ayres (appointed 22 June 2022)

Chief Executive

Mr A Orhan

Independent Examiner

Moore Kingston Smith LLP 6th Floor, 9 Appold Street, London EC2A 2AP

Accountants

JS2 Limited 1 Crown Square, Woking, Surrey GU21 6HR

Legal advisors

Registered Of fi ce

60 Gray’s Inn Road, London WC1X 8AQ

Tel 020 3745 7310 www.orchid-cancer.co.uk

Registered in England with the Charity Commission No.1080540

Company Limited by Guarantee Registered in England No. 3963360

Farrer & Co 66 Lincoln’s Inn Fields, London WC2A 3LH

Bankers

HSBC Plc 20 Electric Parade, George Lane, South Woodford, London E18 2LX

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Inside this report:

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Welcome 6 CEO’s letter 7 1 . The year in review 8 2. Fundraising 16 3. Our impact 20 Prostate cancer 22 Testicular cancer 24 Penile cancer 26 Research 28 4. The year ahead 30 5. Governance 36 Objects, operating context and activities 38 Structure, Governance and Management 38 6. Financial review 42 Formal statements 44 Independent Examiner’s information 45 Independent Examiner’s Report 46 Statement of nancial activities 47 fi Balance sheet 48 Statement of cash ows 49 fl Notes to the nancial statements 50 fi

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Welcome from our Chair

Orchid has again worked tirelessly throughout the year, to support those affected by prostate, testicular or penile cancer. As well as to help people understand the risk factors of male cancers and to prevent the worst prognoses in the future.

To this end, we have continued to invest in world-class male cancer research to bene fi t both current and future generations of men. Orchid’s roots are in male cancer research, our past studies have signi fi cantly advanced the understanding of male cancers. Building on this, the Trustees and I agreed further funding for the Robert Lane Tissue Bank. Led by Professor Dan Berney MB B Chir, MA, FRCPath, the work focusses on translating research into practical interventions for patients via novel tests and bespoke predictive treatments.

Led by our CEO Ali Orhan, in his capacity as Director. Orchid has made excellent progress on our three-year programme: ‘Overcoming the Barriers to Engaging with Prostate Cancer’, funded by the National Lottery Community Fund. Through this substantial piece of work, Orchid will be reaching men at high risk and in some of the most deprived areas of the country.

Cornes, presenting a session at the European Association of Urology (EAU) conference in Milan in 2023, together with Orchid’s patient advocates.

Securing funding in these tricky times has become more of a challenge, and we expect this to continue. However, I am delighted to report that Orchid increased its fundraising effort as per our strategy and gained a signi fi cant increase in income, which puts us on secure ground to continue our work.

Orchid’s work is only possible because of the dedication of our staff, the commitment of our volunteers and the generosity of our supporters. The trustees and I are incredibly grateful to everyone who contributed towards our efforts in the last year, and offer a warm welcome to those who will support us in the year ahead.

Colin Osborne MBE

Work is ongoing to increase the number of peer support opportunities in collaboration with a variety of other organisations. This is as an effective and personal way to provide information and support to those affected by a male speci fi c cancer. Orchid’s collaborative working approach means that Orchid not only shares its expertise, but reaches more men and relevant healthcare professionals, with our information and advice. One highlight next year will be our Specialist Nurse Rob

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

CEO’s letter

It was a successful year of delivering against our objectives. As we emerged from COVID-19 restrictions, we were able to reach those at risk, especially people from marginalised communities, by delivering our Male Cancer Information Roadshows in the heart of local communities, reaching over 8,000 people with information and support.

We were able to maintain increased operational hours for Orchid’s con fi dential Male Cancer Helpline and therefore sent a greater number of referrals to the penile and testicular cancer telephone counselling service. The Overcoming the Barriers to Engaging with Prostate Cancer project is fully underway and almost 4,500 people received prostate cancer information from Orchid’s trained Volunteer Community Champions. We are extremely grateful to the Task-Force members who help to drive this project. Orchid also identi fi ed the need to reach out to trans women who may be at risk of prostate cancer, and we thank the National Lottery Awards for All England for their grant to begin this work.

We worked in many collaborative partnerships this year such as with breast cancer charity CoppaFeel! to produce posters for schools to raise awareness of breast and testicular cancer. We also inputted into a series of four new videos about testicular health by the British Fertility Society.

and that it achieves the PIF TICK quality mark for UK health information.

We want to ensure that information about the three male-speci fi c cancers, our resources and Nurse-led support services reaches more people via the development of a new Orchid website and our social media platforms. We already use online and digital platforms to good effect to disseminate male cancer messages, promote educational fi lms, encourage people to view and download information, inspire people to donate and also access further services and support, and we want to build further on this.

As we face an uncertain economic climate in the UK, Orchid will continue to keep a diversi fi ed fundraising strategy by including individuals as well as Corporate and Charitable Trust supporters.

I am extremely grateful to those who have made our successes possible – not only our dedicated staff, trustees, volunteers, and patient advocates, but also our donors, Corporate partners, new and existing loyal supporters, organisations with which we collaborate to help reach new audiences, and people who have shared their personal stories to help us raise awareness of prostate, testicular and penile cancer.

Ali Orhan, CEO

As we look forward, Orchid will be aiming for excellence in its health information and the team will be reviewing our information assets to ensure that it is the most up to date

----- Start of picture text -----
Orchid Cancer Appeal | Annual report and fi nancial statements 2021-2022
----- End of picture text -----

The year in review Fundraising Our impact The year ahead Governance Financial review

Welcome CEO’s letter

The year in review

Increased helpine hours maintained Roadshow programme reaches targeted communities

Penile cancer advocate performs at Edinburgh Fringe

New resources launched

Supporting research for practical treatments

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

There are more than 55,000 new cases of prostate, testicular and penile cancer each year in the UK. Sadly around 12,000 people will die from these diseases, but thankfully, many will also recover. In response, Orchid has worked throughout the year to support those affected, as well as to help people understand the risk factors, changes to look out for, and the need to get help as soon as possible if concerned. The charity has also continued to invest in world-class male cancer research to bene t both current fi and future generations of men.

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Orchid’s Freephone con fi dential Male Cancer Helpline has remained at the heart of the charity’s Nurseled services, and the increased hours introduced in response to the COVID-19 pandemic continued.

The number of calls taken by our Nurse was in line with the previous year, but an increased number of referrals to the penile and testicular cancer counselling service were made. The peer support sessions which Orchid help facilitate were delivered both virtually and in person, and Orchid Nurse Rob Cornes continued to support the St Bartholomew's Testicular Cancer Support Group.

Reaching those at risk was a priority, especially people from marginalised communities who may not engage with mainstream health messaging. Orchid was active delivering Male Cancer Information Roadshows in the heart of local communities in targeted locations from Aberdeen to Lancaster, and Derby to Hackney. Orchid met over 8,000 people via the Roadshow programme, with others learning about male cancer via the Health at Work programme and awareness talks. In addition, almost 4,500 people received prostate cancer information from the Orchid Volunteer Community Champion team via the Overcoming the Barriers

following one of these shows for other survivors and health care professionals working in the fi eld of penile cancer.

to Engaging with Prostate Cancer project. Orchid has also identi fi ed the need to reach out to trans women who may also be at risk of prostate cancer, and a grant was received from the National Lottery Awards for All England to begin this work.

In recent years reaching people digitally has become increasingly effective and both Male Cancer Awareness Week and International Penile Cancer Awareness Day were driven by social media. Social media content over the year has also been used to share male cancer information as well as links to direct people to the Orchid website, and to the portfolio of paper based and online resources such as our PSHE Association accredited lesson plan and the Your Privates testicular cancer microsite.

In August 2022 Orchid supported comedian Mr Richard Stamp, a penile cancer survivor and advocate, who performed his one man show about his experience of penile cancer at the Edinburgh Fringe Festival for three weeks. This show is a hard-hitting journey through his diagnosis and treatment and won critical local acclaim. Orchid organised and supported a support meeting

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

A new poster series included one for each male cancer, one about all three, and one on how to access Orchid’s support and information

A number of new resources were developed and launched in the year to support our awareness activities. These include a fold out 3 in 1 lea fl et about all three male-speci fi c cancers called “Prostate, Testicular and Penile Cancer. Get to know the facts and how to spot them,” as well as a series of fi ve posters. The poster series has one about each male cancer, one

about all three, and one about the support Orchid can offer. Orchid was pleased to contribute to an initiative created by breast cancer charity CoppaFeel! to produce downloadable educational posters for schools to raise awareness of both breast and testicular cancer, as well as to a series of four new videos about testicular health by the British Fertility Society.

In the period Orchid Nurse Rob Cornes began a review of Orchid’s information with view to attaining the PIF TICK which is the UK-wide Quality Mark for Health Information. Orchid also started work on the development of a new website to offer more accessible information about all three male cancers, collaborated with Ansar Projects and

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

CoppaFeel! on the development of testicular and breast cancer resources to support people with a learning disability to know their body, started making a fi lm called Take Three which will tell the stories of people affected by each of the male cancers together with a booklet telling nine real life stories, and a fi lm about advanced prostate cancer.

Orchid also worked in close

collaboration with health and social care professionals, policy makers and other cancer charities to bring about positive change for men and their families. Examples include continuing to work with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer throughout the

UK, and with both Prostate Cancer Research and TACKLE Prostate Cancer on promoting the activities the different charities carry out.

Research is vital to understand why men develop prostate, testicular and penile cancers and to improve diagnosis and treatment. This is why Orchid continued to support worldclass research by making a grant towards the Robert Lane Tissue Bank incorporating the Circulating Tumour Cells (CTCs) project. The work in the Tissue Bank is focused on the pathology and natural history of prostate, testicular and penile cancer, and on translating basic research into practical treatments for patients with novel tests and bespoke predictive treatments. Circulating Tumour Cells (CTCs) are held in the Tissue Bank for experimental research about cancer genetics and circulating biomarkers, including Circulating Tumour Cells.

Having previously reviewed training need, our small staff team undertook Diversity and Inclusion training, and two bespoke sessions on the use of our fundraising database.

A fold out 3 in 1 lea fl et about all three male-speci fi c cancers was launched

We continued to work in collaboration with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

23,351

pieces of specialist information requested by individuals, organisations and healthcare professionals 184,104 page views on the Orchid website

4,821

people received prostate cancer information from Orchid Community Champions and other experienced volunteers

3,693

men, women and healthcare professionals had in-depth male cancer support or information directly from an Orchid Nurse / Male Cancer Information Manager

24,096

pieces of specialist information disseminated through outreach activities

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

5,400

sessions on Your Privates testicular cancer microsite

824,734 Organic reach of Orchid's social media platforms

8,195

people had the opportunity to learn about male cancer by attending an Orchid Roadshow

Number of peer reviewed papers to which Robert Lane 26 Tissue Bank contributed

100

testicular and penile cancer counselling sessions delivered

----- Start of picture text -----
Orchid Cancer Appeal | Annual report and fi nancial statements 2021-2022
----- End of picture text -----

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Fundraising

Signi fi cant growth in funds raised Support for cancer research

Payroll giving a growing source of unrestricted funds

Jonathan Freedland’s Radio 4 Appeal for Orchid

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Fundraising

Working to save the lives of those diagnosed with prostate, testicular or penile cancer is only possible because of the generosity of our wonderful supporters, be they individuals, community groups, Trusts and Foundations or Companies.

Throughout a successful fundraising year, so many people gave donations because of having been touched in some way by male cancer and in memory of loved ones. The Orchid team cheered on supporters at large events such as the London Marathon and London Landmarks Half Marathon, as well as helped and encouraged the many individuals and groups who were busy fundraising across the UK through activities such as cake sales, the Twyford Beer Festival, running events, our new step challenge, and art events.

There were some signi fi cant grants during the year from Charitable Trusts and Companies restricted to developing innovative information resources, delivering Nurse-led services to support those affected, and reaching out to raise awareness in the heart of local communities. Considerable support was received to fund male cancer research, and a grant was received from the National Lottery Awards for All England to fund a project called “Trans women get prostate cancer too.” Payroll giving continued to be a growing and valuable source of unrestricted income. Furthermore, two legacy payments made a remarkable contribution to income in the year.

A total of £841,808 was raised during the year which showed signi fi cant growth on £530,278 raised in the previous year. Each donation and grant given was a vital contribution, and Orchid would like to thank everyone who helped us in any way as income was regrown after the negative impact of COVID-19.

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Incorporating learnings is important to Orchid. Throughout the year Orchid staff and Trustees continued to review our fundraising activities and sought to identify new opportunities to ensure we retain a diverse and cost-effective fundraising base to balance risk in the years ahead.

During the year we moved to the Fundraise Up platform to engage more supporters and improve the donor experience.

Orchid continually strives to meet and maintain high standards in all areas of fundraising and recognises the importance of listening to and

putting supporters at the centre of everything that we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies.

Orchid operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board of Trustees.

As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with any external agencies we engage to help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves. During the year we received one complaint in relation to our fundraising activities which was resolved in line with our procedures. We remain committed to improving our practice, learning from supporter feedback.

Radio 4 Appeal

Orchid was delighted to be selected as a bene fi ciary of the weekly BBC Radio 4 Appeal. Furthermore, we were thrilled that leading broadcaster and journalist, Jonathan Freedland, was able to present Orchid’s Appeal which went out on Easter Sunday 2022.

In the Appeal, Jonathan spoke very movingly of his own family experience of prostate cancer, telling listeners that his grandfather and father had both been diagnosed with this cancer which now affects over 52,000 men each year. He also shared the story of Orchid supporter, Glenn, who was stunned to be diagnosed with testicular cancer at the age of 55. Like many, Glenn had believed that testicular cancer only affected younger people. Jonathan

spoke about Glenn’s relief at fi nding the support of Orchid’s Male Cancer Nurse Specialist after he called our con fi dential Helpline. Jonathan also explained how speaking to an Orchid Nurse gave Glenn a better understanding of the potential impact of the cancer on his physical and mental health, which made him less fearful. The Appeal focused

on Orchid’s Helpline which is run by Specialist Nurses. It also highlighted the continued need for donations to meet the demand by those seeking support and information about their prostate, testicular or penile cancer concerns. BBC Radio 4 listeners were generous in their support, and together they raised £16,109 towards Orchid’s work.

Jonathan Freedland, journalist, author and broadcaster, who presented Orchid’s Radio 4 Appeal on Easter Sunday 2022

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Our impact

Prostate cancer Testicular cancer Penile cancer Research

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Our impact Prostate cancer

Over 52,000 people are diagnosed with prostate cancer in the UK annually, that’s more than 140 people every day. Sadly, there are 11,855 deaths from prostate cancer each year with 10-year survival at around 78%. According to CRUK, one in six UK males will be diagnosed with prostate cancer in their lifetime.

With more and more men being diagnosed with prostate cancer it is becoming more essential to correctly identify those who may be at risk of disease progression and those with mild or inactive disease.

One of the interesting directions that this may take are so called liquid biopsies - the sampling of circulating cancer cells within the blood. Orchid has helped fund research into circulating tumour cells or CTCs and this method along with a more frequent use of MRI scans to identify potential areas of prostate cancer may improve medical assessment dramatically and reduce the side effects men may experience from cancer treatment.

In addition, those men with minimal risk of disease progression are likely to be managed by active surveillance. This is an option that is likely to increase dramatically over the next few years and one which Orchid has already created information about.

Some men who are put on active surveillance may take 6-months or more to adjust to the fact that their cancer does not require immediate treatment and Orchid has responded to the need for information and support to help them.

One of the greatest challenges around prostate cancer remains the unequal risk of this cancer among Black African and Black Caribbean men who are twice as likely to develop prostate cancer than Caucasian men. Creating awareness in this community and helping support Black men diagnosed with prostate cancer is crucial. Although there are over 95 prostate cancer support groups in the UK, the Black community remains underrepresented.

A need also exists to reach trans women and non-binary people assigned male at birth with prostate cancer messaging, as they too can be diagnosed with this cancer.

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Overcoming the Barriers to Engaging with Prostate Cancer

May 2021 saw the start of a threeyear project funded by The National Lottery Community Fund entitled Overcoming the Barriers to Engaging with Prostate Cancer. This work is led by Ali Orhan in his capacity as Project Director, alongside his role as Orchid CEO.

The project is running in Birmingham, Bradford, Bristol, Dudley, Leeds, Liverpool, Manchester, Newcastle, Nottingham and Wolverhampton, and was gaining real momentum as we entered the reporting year.

Throughout the 12-month period a growing number of Volunteer Community Champions were recruited and trained. Our team – which numbered 82 by the year

end – comprises community

and GP surgeries; by virtual talks; attending men’s groups; the Amazon Distribution Centre in Newcastle; the Armed Forces Day in Wolverhampton; and via food banks.

members, healthcare professionals and prisoners, and they cascade prostate cancer messages using the tool kit and lea fl ets developed by the Orchid project team, as they target those at risk within their own communities.

Trained Community Champions also cascade prostate cancer in three prisons – HMP Dovegate, HMP Stafford and HMP Oakwood. Some of the training had been delayed because of COVID-19, but despite this, these Champions reached 337 men and had 109 in-depth conversations.

In the year, our Volunteer Community Champions reached 4,488 people with prostate cancer information. They had 1,114 in-depth conversations about this cancer, with evaluation showing the difference this made to the bene fi ciaries. 4,642 prostate cancer lea fl ets were disseminated, plus a further 3,503 lea fl ets

In Orchid’s fi nancial year 2022-2023, Orchid will be returning to the ten locations to meet with the teams of Volunteer Champions to celebrate their successes and to discuss the challenges, sharing regional learnings to all the Volunteer Community Champions. The Orchid team will be discussing the case studies reported by the Champions, as well as looking forward to determine how prostate cancer awareness can continue after the project ends in May 2024, and to ensure there is a positive project legacy in each location.

signposting people to local services. The largest group reached were men, but women also were keen to gain knowledge for the men in their lives.

Our Champions used their own local knowledge to inform their choice of awareness raising activities. Some examples included: talking to and reaching people via information stands in libraries; health and other community events including festivals; on buses and trains; in markets, taxis,

Our Volunteer Community Champions reached 4,488 people with prostate cancer information. The largest group reached were men, but women also were keen to gain knowledge for the men in their lives.

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Our impact Testicular cancer

Testicular cancer is rare with around 2,300–2,400 diagnoses each year in the UK. Around 60 men will die each year from testicular cancer although it remains potentially the most treatable and curable type of cancer with over 90% of men surviving 10 years.

Testicular cancer tends to affect a younger age group than most other cancers, with nearly 50% of men diagnosed under the age of 35, and 80% of those diagnosed between the ages of 15-45. This means that testicular cancer will often affect men at a stage of their life where they may be starting a family or career, or just consolidating their place in life. Treatment occurs quickly with men often being diagnosed and treated within a few weeks.

As well as surgery to remove the affected testicle, treatment may also involve chemotherapy. In addition to temporary side effects, chemotherapy can increase the risk of cardiovascular disease in later life.

Challenges around testicular cancer involve supporting men in adjustment

to life following treatment. Many men will only realise the full implication of their cancer journey when treatment ends and may not be able to access either peer support or psychological support. Orchid has consistently supported the biggest testicular cancer support group in the UK, which is co-ordinated by the specialist nurse team at St Bartholomew’s in London, both physically and virtually.

In addition, the creation of Orchid’s telephone counselling service allows men to access psychological support without the necessity of waiting for extended periods of time.

Orchid also continues to work with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer throughout the UK.

Testicular cancer is the most common cancer in young men – many older men are not aware they remain at risk and may ignore potential symptoms.

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Male Cancer Awareness Week 2022

your GP if concerned. The theme of the Awareness Week in 2022 was ‘Older Men Get Testicular Cancer Too!’

Male Cancer Awareness Week

unites individuals and organisations from around the UK to help raise awareness of prostate, testicular and penile cancer.

and penile cancer. Due to the period of National Mourning following the death of Every year the week highlights the Her Majesty Queen Elizabeth II, importance of being aware of the risk Orchid delayed its Male Cancer factors and early signs or symptoms Awareness Week which was of these three cancers, and the planned for 12th to 18th September, importance of getting checked out by until 26th September to 2nd October.

The messaging was delivered mainly digitally with a series of infographics delivered each day across Orchid’s social media, and that of partners and supporters, as well as by targeted advertising. Testicular cancer is the most common cancer in young men and many older men are not aware they remain at risk and may ignore potential symptoms.

The infographics and accompanying text covered the risk factors, the potential signs and symptoms, and how men can check their testicles to understand what is normal and what may be a potential sign of this cancer. Our posts also highlighted the information available on the Orchid website, and that the Orchid Helpline run by experienced Male Cancer Nurse Specialists is there for anyone with a concern.

Through Orchid’s own social media channels, we had an organic reach of over 6,500 with these important messages.

Paid social media advertising and radio coverage took the total number of opportunities to learn about testicular cancer to over 422,500.

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Our impact Penile cancer

Penile cancer is exceptionally rare in the UK with around 700 men being diagnosed each year. Around 170 men will lose their lives to the disease although 68% of men will survive 10 years following their diagnosis.

Most men will never meet another man affected by penile cancer, so Orchid has focused on developing a telephone counselling service to support men and has created events to offer peer support.

Out of the three male-speci fi c cancers, penile cancer has the potential to cause the most physically and psychologically damaging side effects, as all curative treatment will involve some form of surgery to the penis itself. This can be minimally invasive but may also involve partial or total amputation of the penis resulting in a radical change in body image and sexual function.

Due to its intimate nature around 15-50% of men will delay seeking treatment. Delaying penile cancer treatment can lead to disease progression of the primary tumour such that organ-sparing surgery may no longer be feasible. In addition, 20-25% of penile cancer may be misdiagnosed with men being referred to dermatologists and sexual health clinics.

Treatment is performed at specialist regional treatment centres in the UK with dedicated teams performing penile sparing surgery.

The main challenges for Orchid around penile cancer are creating awareness of the disease – many people do not realise penile cancer exists, and the isolation which men may feel following treatment. Most men will never meet another man affected by penile cancer due to its

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

rarity therefore missing out on invaluable peer support. In addition, there is an unmet need to support these men psychologically. When men realise that they may need psychological help such as counselling there is often a severe delay in referral.

Orchid has therefore focused on the development of a telephone counselling service to support men and wherever possible has created events to offer peer support, as well as supporting and encouraging allied healthcare professionals in the creation of regional support groups.

Orchid’s collaborative work

Orchid is pleased to continue its collaborative work with the European Reference Networks (eUROGEN) to improve the patient pathway for men with penile cancer across Europe. In addition, Rob Cornes is now a member of the EAU Patient Advocacy Group representing both testicular and penile cancer on behalf of Orchid.

In August 2022 Orchid Nurse Rob Cornes and two men with penile cancer, who have been supported and empowered by Orchid to act as Patient Representatives or ePAGs, gave a lecture at the European Association of Urology (EAU) Conference in

With 83 cases a year, there is a higher incidence of penile cancer in Scotland in comparison to the rest of the UK, and those affected by penile cancer in Scotland are also being diagnosed at a younger age. A penile cancer diagnosis can be psychologically devastating, and treatment can be challenging especially if the diagnosis has been made at a late stage.

Orchid has signi fi cant experience of educating people about the signs and symptoms of penile cancer, as well as understanding the complex

Amsterdam. This session highlighted the unmet needs of penile cancer patients and was based on a peer reviewed article written by Rob Cornes and published in the prestigious journal Seminars on Oncology Nursing.

Orchid is working collaboratively with eUrogen and is in the process of creating a suite of resources about penile cancer. These resources will consist of two humorous awareness videos, one aimed at the general public to raise awareness of penile cancer and the other to encourage GPs and primary care workers to refer men with any suspicious penile lesion urgently to a urologist. A further animated video is being scripted by Rob Cornes and created by the EAU

issues involved in supporting penile cancer patients.

Whilst we do not as yet know why Scotland has a higher incidence proportionally than the rest of the UK, we do know that many people have not heard of penile cancer, let alone know what potential symptoms might be. This is why Orchid identi fi ed the need to deliver a project to put penile cancer on the agenda in Scotland, and whilst delivery of this speci fi c piece of work is complete, many of the elements have now been brought into Orchid’s core services.

about penile cancer. With further funding a future video will be created dealing with management strategies for men living with the side effects of the disease. A patient experience booklet will also be created to provide guidance for health care professionals caring for penile cancer patients.

During the year Orchid also joined the Human Papilloma Virus Coalition, a consortium of numerous charities working in the fi eld of HPV education, awareness and prevention. Regular meetings and collaboration will continue over the next few years. Around 50% of men diagnosed with penile cancer will have evidence of certain types of HPV infection which increase the risk of the disease.

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Our impact Research

Orchid was pleased to continue its support for the work of The Robert Lane Tissue Bank incorporating the Circulating Tumour Cells (CTC) project during the year.

Ongoing work includes:

TAPG (the study with the Trans-Atlantic Cohort). Further papers are ongoing, with one in ‘major revision at present’ and another in preparation.
Testis. Further collaborative work with Denmark continues, with 2/3 papers in preparation for 2023.
A new collaboration looking closely as Sex cord stromal tumours of the testis has just been initiated. This International collaboration has support for 2023 from two international pathology organisations (The International Society of Urological Pathology (ISUP) and The Genitourinary Pathology Society (GUPS) for these challenging to treat tumours.
STAMPEDE. Work is ongoing for publication in 2023/24. (STAMPEDE is a clinical trial looking at the best way of treating men with newly diagnosed advanced prostate cancer.)
Review a manuscript on using CTCs for early detection of aggressive cancer: a synopsis has been submitted to Nature Review Clinical Oncology (Impact factor 62) and approved by the editors for full manuscript submit (to be submitted in January 2023).
CTC clusters as prostate cancer prognostic biomarkers: a manuscript to be completed in 2023.

During the period, Orchid funded work has contributed to the following books:

Chapter: Testicular Neoplasia. Sternberg's Diagnostic Surgical Pathology (2 Volume Set) 2022.
Urinary and Male Genital Tumours. WHO Classi fi cation of Tumours, 5th Edition, Volume 8 WHO Classi fi cation of Tumours Editorial Board
A full list of papers for the period is available on request.

The Robert Lane Tissue Bank is headed by Professor Dan Berney, MB BChir, MA, FRCPath who is an Honorary Professor of Genito-urinary Pathology; Consultant Pathologist. Professor Berney has lectured throughout the world and is an internationally recognised pathology expert in the three male genito-urinary cancers.

Professor Yong-Jie Lu MBBS, MD, PhD, and Professor of Molecular Oncology, who leads the Circulating Tumour Cells Project, has worked on cancer genetics research for 30 years. Professor Lu has developed a number of novel cancer genetic analysis techniques and was fi rst to identify the genetic difference in prostate cancer between the Chinese and Western population.

The Robert Lane Tissue Bank is an internationally signi fi cant resource for past and future research into all three male-speci fi c cancers. Rather than collecting all tumours, it is a ‘bespoke’ bank often with long term clinical follow up and connected to clinical trial data. It holds tumours from nine separate clinical trials; over 600 penile cancer specimens, over 3,000 testicular cancer specimens, and over 6,000 prostate cancer specimens; and more than 1,200 blood samples collected and separated into Circulating Tumour Cells (CTCs), plasma, red blood cells,

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

white blood cells and platelets for separate storage and future research.

In 2022 The Robert Lane Tissue Bank contributed to 26 peer reviewed papers. This record-breaking number included 10 papers where, although the Tissue Bank had contributed data as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium, Professors Berney and Lu were not a named author, nor any other consortium member. This was changed as an Author correction to these papers in December 2022. The papers were published in 2020-2022 and have not previously been mentioned in Orchid’s work. Many are now highly cited. This emphasises how the tissue collection has made a huge

contribution to international research. Abstracted work was presented at the United States and Canadian Academy of Pathology USCAP 2022 meeting in March on prostate cancer (accepted platform presentation) in Los Angeles, and at the European Congress of Pathology in September in Basel.

The Circulating Tumour Cell (CTC) and biomarker studies have shown that CTCs and gene expression analysis can predict prostate cancer patient response to the chemotherapy drug docetaxel with a manuscript accepted recently by Frontiers of Oncology. Blood samples (over 200) have been collected from prostate cancer patients, patients with suspected prostate cancer and

Over 200 blood samples have been collected from prostate cancer patients and healthy volunteers, and stored for future research

healthy volunteers, with CTCs isolated and other blood components separated and stored in -80[o] C freezer (over 1000 items) for future research.

Further CTC analysis con fi rmed that CTC positivity predicts prostate cancer aggressiveness and biopsy outcome. It also showed that CTC clusters (two or more CTC stick together in the blood) are associated with aggressive prostate cancer and a manuscript is in preparation.

CTC work as prostate cancer diagnostic and therapeutic biomarkers has been presented as invited talks at the 2021 UK National Cancer Research Institute Annual Meeting (November 2021); The BioTech Pharma Summit 2021 – Antibody Engineering Biomarkers Biobanking and Liquid Biopsy (Porto, November 2021); Prostate Cancer UK Spotlight on... webinar series – Spotlight on blood biomarkers (June 2022); Public Policy Exchange webinar series – Improving Cancer Screening in the UK (August 2022); 4th Annual Biomarker and Companion Diagnostics Conference (London, October 2022); 8th Taihu Chinese Urological Symposium and 8th Huishan Precision Medicine Summit (Wuxi, China, November 2022); and European Liquid Biopsy Society Circulating Tumour Cell technology workshop (December 2022).

----- Start of picture text -----
Orchid Cancer Appeal | Annual report and fi nancial statements 2021-2022
----- End of picture text -----

----- Start of picture text -----
4.
30
----- End of picture text -----

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

The year ahead

New lm to start conversations about fi male cancer

Booklet to highlight nine real life encounters with cancer

Support for people with learning diabilities to know their body New website to be launched More Volunteer Community Champions to be recruited

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

The year ahead

The reporting year ended with the successful delivery of Orchid’s fourteenth Male Cancer Awareness Week which, whilst highlighting all three male-speci fi c cancers, had a particular focus on “Older men get testicular cancer too.” Knowing that male cancer is easier to treat and cure if it is discovered early, raising awareness of male cancer risk factors, signs and symptoms remained a priority as we entered the new fi nancial year.

Plans were in place to launch new educational resources in the early part of the year including two new fi lms. Take Three will tell the story of three people affected by male cancers to start important conversations, and a fi lm will help those diagnosed with advanced prostate cancer better understand their condition. Work will also start on another fi lm which will be used to deliver targeted prostate cancer messages as well as providing information and support to those diagnosed.

Other resources to be launched early in the year include a booklet which will describe nine real life encounters with prostate, testicular and penile cancer. Again, its aim is to encourage

Plans are in place to launch new resources in the early part of the year which will start important conversations about male cancers

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

people to talk about these cancers and to learn what to look out for. Another addition to our portfolio will be a series of accessible resources developed with Ansar Projects and CoppaFeel! to support people with a learning disability to know their body. The resources will be the fi rst of their kind and will include accessible testicular and breast cancer information packs, self-checking cards, testicular and breast cancer symptom guides, self-checking social stories and information on what to expect if you notice a change.

December will see the launch of the new Orchid website, with more accessible information and resources which will be available to order and download. The review of Orchid’s information is ongoing with view to attaining the PIF TICK, the UK-wide Quality Mark for Health Information.

Community outreach will continue with Orchid’s successful Male Cancer Information Roadshows run in targeted identi fi ed locations, delivered as funding is received. Alongside Roadshows, talks and presentations, Orchid plan to grow its Health at Work

programme. Plans are in place to recruit and train further Volunteer Community Champions through the National Lottery Community Fund project, Overcoming the Barriers to Engaging with Prostate Cancer. The project team are in regular contact with those who are already using their knowledge of their local communities to cascade prostate cancer

information to support their outreach, and the learnings coming out of regionally based conferences planned for Spring 2023 will be shared widely.

Orchid’s Male Cancer Awareness

Week will take place between 11-17 September 2023, leading on to the third International Penile Cancer Awareness Day.

Supporting those affected by male cancer is also a high priority for the coming year. The Freephone National Male Cancer Helpline will continue to operate its increased hours for anyone worried about prostate, testicular or penile cancer. We also remain committed to delivering and cofacilitating peer support opportunities. In collaboration with the Maggie’s Centre at the Christie Hospital in

Manchester, Orchid will help run a

penile cancer support group every two months. A similar group had been set up prior to the pandemic as a direct result of an Orchid initiative. Now the group will reform in 2023 and working with the Christie penile cancer team Orchid will seek to further its contacts within this community. We will continue to offer a telephone counselling service to those affected by penile or testicular cancer.

Social media will be used to relay male cancer messages, promote our educational fi lms and to drive followers to the Orchid website or to view, order or download resources. Posts will be developed incorporating the learnings of the last year when we found that the audience was more reactive to awareness and personal stories.

Orchid Nurse Rob Cornes works with healthcare professionals both in the UK and beyond to improve the patient journey for those with penile cancer. Orchid resources and services will be promoted throughout the year to healthcare professionals working in the relevant fi elds throughout the UK.

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Through his work with the European Reference Networks (eUROGEN) Rob Cornes and the patient advocates Orchid identi fi ed will present a further session on communicating accurate medical information to patients for rare cancers at the European Association of Urology (EAU) conference in Milan in 2023. In addition, Rob Cornes, who is now a member of the EAU Patient Advocacy Group representing both testicular and penile cancer on behalf of Orchid, will provide two further talks at the upcoming EAU 2023 conference and take part in two panel discussions.

Orchid’s roots are in male-cancer research. In recent years Orchid funded research has signi fi cantly advanced understanding of male cancers, and we will continue to invest in world-class male cancer research to bene fi t the well-being of current and future generations of men. Going into the year, Trustees agreed further funding for the Robert Lane Tissue Bank. The Tissue Bank is led by Professor Dan Berney MB B Chir, MA, FRCPath and is an internationally important resource for research into penile, testicular, and prostate cancer. Professor Berney is focused on translating basic research

Social media will be used to relay male cancer messages and to drive followers to the Orchid website

into practical treatments for patients with novel tests and bespoke predictive treatments.

Donations have been received for the Orchid Research Innovation Fund. Trustees plan to award a signi fi cant grant from funds secured in the coming year.

Securing adequate funding at the best possible return on investment is essential to deliver our ambitious plans for the year ahead. After seeing income increase in 2021-2022, our fundraising strategy for 2022-2023 focusses on growing revenue further across all income streams.

The new year started with a wonderful team of runners fundraising for Orchid in the London Marathon, and 2023 will see both existing and new supporters taking part in a number of different running events, as well as in Orchid’s unique Willy Waddles in London and Edinburgh. We are grateful to our supporters who are planning events such as a charity ball, a cycle ride and beard competitions, in addition to the annual and extremely successful Twyford Beer Festival.

We will continue to submit application to Charitable Trusts and

----- Start of picture text -----
34
----- End of picture text -----

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Foundations on a rolling basis, and carry out research to identify new potential supporters. We will work with our corporate supporters to meet their needs as well as Orchid’s and will explore corporate opportunities in the areas in which the Overcoming the Barriers to Engaging with Prostate Cancer project is running. We will also continue to explore other new income generating opportunities.

We will explore corporate opportunities in the areas in which our Overcoming the Barriers to Engaging with Prostate Cance r project is running

Looking after our supporters is paramount. We will continue to offer the best possible support to our corporate partners, the Charitable Trusts and Foundations who give to us, and all the individuals and community groups who support us with donations and fundraise on our behalf.

Orchid recognises its responsibility to reduce its carbon and environmental footprint and will continue to monitor its activities in relation to our Environmental Policy.

Orchid’s work is only possible because of the generosity of our supporters. We are grateful to everyone who contributed towards our work in the last year, as well as to those who will support us in the year ahead.

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Governance

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Orchid’s aim is to provide greater knowledge and awareness about male speci fi c cancers by funding scienti fi c and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing information about them to people throughout the UK.

Objects, operating context and activities

Objects

Over 55,000 people in the UK are diagnosed with prostate, testicular or penile cancer every year and sadly this number is increasing. Orchid’s aim is to provide greater knowledge and awareness about male speci fi c cancers by funding integrated scienti fi c and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those affected.

Operating context and activities

Orchid's aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our in fl uence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers,

how they work, possible causes and to identify new treatments and enhance care. Support and information delivered by our Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

Structure, governance and management

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chair’s aim to maintain a balanced composition. Applications from individuals seeking to become a Trustee will be

considered as and when appropriate by the Board. The Board meet four times during the year and, at the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from of fi ce in rotation, in order of longevity of appointment and are eligible to be reappointed.

Throughout the COVID-19 pandemic Trustees met virtually and continued to do so in 2021-2022.

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Trustee training and induction

On appointment, Trustees are offered a comprehensive induction programme which includes a meeting with the lead programme researchers and visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

Delegation and decision-making

The decision-making process operates as follows:

At the strategic level, the Board of Trustees regularly reviews Orchid’s direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.

The Finance Committee is responsible for the fi nancial oversight of the Charity including budgeting, fi nancial planning and monitoring as well as fi nancial reporting and the creation and monitoring of internal controls and accounting policies. It presents a

report to the Board at each of its meetings. As at 30 September 2022, it comprised the Honorary Treasurer, Mr W Cohen, Mr C Osborne, Mr M Kibblewhite, Mr S Seymour and Mr S Harris. To improve ef fi ciency,

Sub-Committees have been reviewed, and the Fundraising Sub-Committee meets as required.

At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept appraised of personnel, awareness, research programme and budgetary issues.

Public bene t

The Trustees con fi rm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public bene fi t including (PB2 Public Bene fi t: Running a Charity).

Key management personnel and remuneration policy

Orchid is committed to attracting and retaining talented staff. Staff are kept

fully informed of the organisation’s strategy and objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for speci fi c tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for new research grants and the veri fi cation of outcomes, a Scienti fi c Advisory

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Board provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and ef fi ciency of research that the Charity currently funds or may consider funding.

Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identi fi es risk and allocates responsibility for managing areas of risk to named individuals. Following Charity Commission recommendations the risk register identi fi es risks under the following headings:

Governance and compliance Operational

Financial

Research

Environmental/external Quality assurance

Each identi fi ed risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identi fi ed and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed regularly and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Governance and compliance

Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to

Mitigation

An ongoing review of the composition of the Board of Trustees to ensure that all key functions, including medical, legal and fi nancial, are covered by suitably quali fi ed professionals
Training and support for Board of Trustees and Finance Committee
Dedicated specialist resource applied in key areas e.g. health and safety, HR and legal
Ensuring that key management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements

Speci fi c risks which, if materialised, would have had a signi fi cant impact on the Charity have been identi fi ed. These are as follows:

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Operational

Attracting, developing and retaining talented staff in a competitive employment market

Mitigation

Annual salary review to include benchmarking of compensation and bene ts
Staff development, training and succession planning programmes
Communication programme to ensure staff are involved in the development of and progress towards Orchid’s strategy and annual workplan

Financial

Economic pressures, impact of COVID-19, competition, fundraising regulatory environment and consumer behaviour changes leading to a signi fi cant fall in income

Mitigation

Annual budgeting and ongoing management, reporting and monitoring of fi nancial performance
Diversi cation of income streams
Ongoing consideration of market and consumer trends and regulations including GDPR

Research

Orchid’s Research Programme fails to deliver results

Mitigation

Scrutiny and approval of research funding applications by an expert Scienti fi c Advisory Board
Annual review of progress

Environmental / external

Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid’s work

Mitigation

Key personnel monitor public policy and the regulatory environment on an ongoing basis to ensure potential risks can be proactively managed
Chief Executive and Nurse Specialists attend key events and forums to help shape agenda
Chief Executive and the Board of Trustees routinely scrutinise alignment with, and progress of, Orchid’s strategy

Quality assurance

Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

Mitigation

Services developed, delivered and evaluated in line with agreed protocol and standards
Nurse Specialists are members of the Royal College of Nursing (RCN) and the British Association of Urological Nurses (BAUN), and registered with the Nursing and Midwifery Council (NMC)
All information materials and content regularly reviewed and updated
High-quality training for staff

----- Start of picture text -----
Orchid Cancer Appeal | Annual report and fi nancial statements 2021-2022
----- End of picture text -----

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Financial review

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Results for the year

Income for the year ended 30 September 2022 totalled £841,808 (2021: £530,278). After total expenditure of £740,252 (2021: £673,004), the year's activities show a net surplus of £101,556 (2021: de fi cit of £142,726). Total reserves at the end of the year amounted to £541,836 (2021: £440,280).

Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £121,808 to help fund the costs of increased

organisational capacity with the Charity. Free reserves are distinct from funds that have been

earmarked or ‘designated’ for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity’s core activity of funding research and awareness during a period of sustained unforeseen dif fi culty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity’s planning, budgeting and forecast cycle. It should take into account:

risks associated with each income and expenditure stream differing from that budgeted
planned activity level
organisational commitments.

The available free reserves net of tangible fi xed assets are £162,113 (2021: £154,187). It is the Charity’s policy to maintain free reserves of approximately 3-4 months of operating costs. At current levels of expenditure this equates to £160,000-£212,000.

Formal statements Statement of Trustees’ responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees’ Report and the fi nancial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare fi nancial statements for each fi nancial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these fi nancial statements, the Trustees are required to:

select suitable accounting policies and then apply them consistently;
observe the methods and principles in the Charities SORP;
make judgements and estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the fi nancial statements;
prepare the fi nancial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the fi nancial position of the charitable company and enable them to ensure that the fi nancial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and fi nancial information included on the Charity’s website. Legislation in the United Kingdom governing the preparation and dissemination of fi nancial statements may differ from legislation in other jurisdictions.

Independent Examiner’s information

So far as each of the directors at the time the Trustees’ report is approved is aware:

a) there is no relevant information of which the examiner is unaware; and

b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant independent examination information and to establish that the examiners are aware of that information.

The examiner, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in of fi ce and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed examiner for the ensuing year.

Signed on behalf of the Trustees

C S Osborne Chairman of Trustees 20/03/2023

The fi nancial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Independent Examiner’s Report to the Trustees of Orchid Cancer Appeal

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 September 2022.

Responsibilities and basis of report

As the charity’s trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (‘the 2006 Act’).

Having satis fi ed myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity’s accounts as carried out under section 145 of the Charities Act 2011 (‘the 2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner’s statement

Since the Company’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I con fi rm that I am quali fi ed to undertake the examination because I am a member of the Association of Chartered Certi fi ed Accountants, which is one of the listed bodies.

I have completed my examination. I con fi rm that no matters have come to my attention in connection with the examination giving me cause to believe:

accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
the accounts do not accord with those records; or

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

James Saunders FCCA DChA

Date: 30 March 2023

For and on behalf of Moore Kingston Smith LLP Chartered Accountants 6th Floor, 9 Appold Street, London EC2A 2AP

the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Statement of nancial activities

(incorporating an income and expenditure account) For the year ended 30 September 2022

Year ended Year ended Unrestricted Restricted 30 September 30 September Note Total Total 2022 2021 £ £ £ £ Income from: Donations and Legacies 2 440,779 233,921 674,700 440,580 Charitable Activities 4 - 166,673 166,673 89,497 Trading Activities 309 - 309 177 Investment income 126 - 126 24 Total income 441,214 400,594 841,808 530,278 Expenditure on: Raising funds Fundraising (donations and grants) 5 185,431 - 185,431 185,083 Charitable Activities Education and Awareness 5 109,874 266,968 376,842 307,383 Research 5 127,859 50,120 177,979 180,538 Total expenditure 423,164 317,088 740,252 673,004 Net income / (expenditure) and net movement in funds 5,6 18,050 83,506 101,556 (142,726) Reconciliation of funds Total funds brought forward 278,966 161,314 440,280 583,006 Total funds carried forward 297,016 244,820 541,836 440,280

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 13 to the nancial statements.

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Balance sheet

As at 30 September 2022

30 September 30 September 2022 2021 Note £ £ £ £ Fixed Assets Tangible Assets 10 3,891 2,971 Intangible fi xed assets 11 9,204 - Current Assets Cash at bank and in hand 590,444 508,854 Debtors 12 108,806 77,325 699,250 586,179 CREDITORS Amounts due within one year 13 (170,509) (148,870) Net Current Assets 528,741 437,309 Total Assets less Current Liabilities 14 541,836 440,280 NET ASSETS 541,836 440,280 Represented by: 15 General Unrestricted Funds 175,208 157,158 Designated Funds 121,808 121,808 297,016 278,966 Restricted funds 244,820 161,314 541,836 440,280

The company is limited by guarantee.

For the year ending 30 September 2022 the charitable company was entitled to exemption from statutory audit under Section 477 of the Companies Act 2006 relating to small companies.

No notice from Trustees requiring an audit has been deposited under Section 476 of the Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The fi nancial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Mr C S Osborne Company number 3963360

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Statement of cash ows

For the year ended 30 September 2022

2022 2021 £ £ £ £ Cash fl ows from operating activities: Net income/(expenditure) for the year 101,556 (142,726) Adjustments for: Depreciation charges 1,944 1,486 Interest (126) (24) (Increase)/Decrease in debtors (31,481) 59,261 Increase/(Decrease) in creditors 21,639 (132,517) Net cash provided by operating activities 93,532 (214,520) Cash fl ows from investing activities: Interest 126 24 Purchase of fi xed asset (12,068) (4,091) Net cash used in investing activities (11,942) (4,067) Change in cash and cash equivalents in the year 81,590 (218,587) Cash and cash equivalents at the beginning of the year 508,854 727,441 Cash and cash equivalents at the end of the year 590,444 508,854 Analysis of cash and cash equivalents Cash at bank and in hand 590,444 508,854 590,444 508,854

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

Notes to the fi nancial statements 1. Accounting policies

For the year ended 30 September 2022

Basis of Preparation

These fi nancial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public bene fi t entity for the purposes of FRS 102 and therefore has also prepared the fi nancial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Charities Act 2011.

Going Concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these fi nancial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these fi nancial statements and have considered the external economic environment on the charity’s operations. In particular, the trustees have considered the charity’s forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future.

Income for 2021-2022 showed considerable growth post the COVID-19 pandemic, and together with careful fi nancial management the charity had stabilised. The accounts for the year show a surplus after a signi fi cant de fi cit in the previous year, leaving historic cash funds in place.

The project funded by the National Lottery Community Fund; Overcoming the Barrier to Engaging with Prostate Cancer will continue to run until May 2024, and there is a strong events and community fundraising pipeline after the disruption of the pandemic. The potential to grow income from Corporate Partnerships and Charitable Trusts and Foundations is recognised, and plans are in place to recruit more regular givers. Fundraising plans allow for income from different funding streams to spread risk. The National Lottery funded project along with continued support from loyal donors and supporters will enable Orchid to continue to as a going concern.

The trustees con fi rm that there are no material uncertainties about the ability of the charity to continue as a going concern. The charity, therefore, continues to adopt the going concern basis in preparing its fi nancial statements.

Functional Currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity operates. The fi nancial statements are also presented in pounds sterling, rounded to the nearest £1.

Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a

purchase consideration in excess of £1,000 are capitalised.

Computer and Of fi ce Equipment - 33 1/3% on written down value

Intangible fi xed assets

Intangible fi xed assets are included in the balance sheet at original cost less accumulated amortisation.

Amortisation is provided on a straight line basis calculated to write down the cost of all intangible assets to their estimated residual values over the number of years of expected use. Assets are amortised at the following rate:

Website - 20% on straight line value

Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for speci fi c purposes.

Restricted funds are funds subject to speci fi c restrictions imposed by donors or by the nature of the appeal.

The purpose and use of the Charity’s restricted funds is set out in the notes to the nancial statements.

Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quanti fi able. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Expenditure

Cost of raising funds includes costs associated with the fund-raising events in furtherance of the Charity’s objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity’s objects.

Governance costs are those incurred in connection with the management of the Charity’s assets, organisational administration, and compliance with constitutional and statutory requirements and are included within support costs

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are ful fi lled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

Financial Instruments

The charitable company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its fi nancial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the fi nancial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic nancial instruments under FRS 102.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Cash and Cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash fl ows, cash and cash equivalents consist of cash and cash equivalents as de ned above.

Creditors

Short term trade creditors are measured at the transaction price. Other fi nancial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

Pension Scheme

The Charity operates a de fi ned contribution stakeholder pension scheme. The amount charged to the statement of fi nancial activities in respect of pension costs is the Charity's contributions payable in the year.

The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee Bene fi ts

The cost of short-term employee bene fi ts are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee’s services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have signi fi cant effect on the amounts recognised in the fi nancial statements nor do any estimates or assumptions carry a signi fi cant risk of material adjustment in the next fi nancial year.

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

2. Donations

Current year Year ended Year ended 30 September 2022 30 September 2021 Restricted Unrestricted Total Total £ £ £ £ Individuals 68,800 118,087 186,887 143,844 Legacies - 100,000 100,000 - Corporates - 36,814 36,814 35,771 Trusts and Foundations 165,121 44,600 209,721 114,300 Fundraising Events - 141,278 141,278 146,665 Total 233,921 440,779 674,700 440,580 Prior year Year ended 30 September 2021 Restricted Unrestricted Total £ £ £ Individuals 92,800 51,044 143,844 Corporates - 35,771 35,771 Trusts and Foundations 97,250 17,050 114,300 Fundraising Events - 146,665 146,665 Total 190,050 250,530 440,580

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

3. Fundraising events

Current year Year ended Year ended 30 September 2022 30 September 2021 Restricted Unrestricted Total Total £ £ £ £ Cycling events - 658 658 11,257 Running events - 68,646 68,646 56,100 Third party organised events - 62,806 62,806 76,943 Other - 9,168 9,168 2,365 Total - 141,278 141,278 146,665 Prior year Year ended 30 September 2021 Restricted Unrestricted Total £ £ £ Cycling events - 11,257 11,257 Running events - 56,100 56,100 Third party organised events - 76,943 76,943 Other - 2,365 2,365 Total - 146,665 146,665

4. Charitable activities

Current year Year ended Year ended 30 September 2022 30 September 2021 Restricted Unrestricted Total Total £ £ £ £ The National Lottery Community Fund 166,673 - 166,673 89,497 RC England-wide Total 166,673 - 166,673 89,497 Prior year Year ended 30 September 2021 Restricted Unrestricted Total £ £ £ The National Lottery Community Fund 89,497 - 89,497 RC England-wide Total 89,497 - 89,497

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

5. Total expenditure

Current year Year ended Year ended Cost of Education and 30 September 2022 30 September 2021 raising funds Awareness Research Total Total £ £ £ £ £ Grants - - 149,222 149,222 154,896 Staff costs 74,399 147,294 18,366 240,059 239,012 Fundraising expenses 68,941 - - 68,941 51,935 Information materials - 98,605 - 98,605 66,371 Direct costs - 38,393 - 38,393 30,322 143,340 284,292 167,588 595,220 542,536 Support costs Depreciation 558 1,248 138 1,944 1,486 Other 33,797 75,514 8,343 117,654 98,477 Governance - staff costs 5,869 11,618 1,449 18,936 24,628 Governance - examiners fees 1,867 4,170 461 6,498 5,877 42,091 92,550 10,391 145,032 130,468 Total expenditure 185,431 376,842 177,979 740,252 673,004 Prior year 185,083 307,383 180,538 673,004

6. Grants awarded

Year ended Year ended 30 September 2022 30 September 2021 Total Total £ £ Grant commitments brought forward 87,576 205,415 Institutional grants for medical research awarded during year/period Orchid Study and Travel Awards (2022: 2 individuals 2021: 0 individual) 2,000 - Barts and London School of medicine 144,652 138,896 Payments made during period/year (107,611) (256,735) Grant commitments carried forward 126,617 87,576 Payable less than one year 126,617 87,576 Payable two to fi ve years - -

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

7. Net expenditure for the period

Year ended Year ended This is stated after charging: 30 September 2022 30 September 2021 Total Total £ £ Depreciation 1,944 1,486 Examiners' remuneration: Examination 5,415 5,300 Payments made during period/year - - Trustees' remuneration - - Trustees' expenses

8. Staff costs and numbers

Year ended Year ended Staff costs were as follows: 30 September 2022 30 September 2021 Total Total £ £ Salaries and wages 205,290 182,602 Social security costs 16,414 13,020 Pension contributions 1,616 1,364 223,320 196,986 Consultant costs 35,675 66,655 258,995 263,641

During the year ended 30 September 2022 1 employee earned more than £60,000 (Year to 30 September 2021: 1). The pension contribution paid in respect of this employee totalled £Nil (2021: £Nil)

The key management personnel of the charity comprise the trustees and the chief executive.

The charity trustees do not receive remuneration. The total remuneration of the chief executive was £78,802 (year ended 30 September 2021: £66,494).

The average number of employees during the year was 7.5 (2021: 6.7)

The average number of employees during the year on a headcount basis was as follows:

2022 2021 No . No. Fundraising 1.7 2.1 Education and Awareness 5.5 4.3 Grant support 0.3 0.3 Overall average 7.5 6.7

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

10. Tangible fi xed assets

Computer and Year ended Year ended Staff costs were as follows: of fi ce equipment 30 September 2022 30 September 2021 Total Total £ £ £ Cost At the start of the period 7,315 7,315 3,224 Additions 2,864 2,864 4,091 At the end of the period 10,179 10,179 7,315 Depreciation At the start of the period 4,344 4,344 2,971 Charge for Period 1,944 1,944 1,486 At the end of the period 6,288 6,288 4,344 Net book value At the end of the period 3,891 3,891 2,971 At the start of the period 2,971 2,971 366

11. Intangible fi xed assets

Website Year ended Year ended Staff costs were as follows: development 30 September 2022 30 September 2021 Total Total £ £ £ Cost At the start of the period - - - Additions 9,204 9,204 - At the end of the period 9,204 9,204 - Depreciation At the start of the period - - - Charge for Period - - - At the end of the period - - - Net book value At the end of the period 9,204 9,204 - At the start of the period - - -

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

12. Debtors

Year ended Year ended 30 September 2022 30 September 2021 Total Total £ £ Prepayments 10,071 45,594 Other debtors and accrued income 98,735 31,731 108,806 77,325

13. Creditors: amounts due within one year

Year ended Year ended 30 September 2022 30 September 2021 Total Total £ £ Grants Payable 126,617 87,576 Trade and Other Creditors 11,113 20,799 Accruals 32,779 40,495 170,509 148,870

14. Movements in funds

Brought forward Income Expenditure Carried forward £ £ £ £ Unrestricted General 157,158 441,214 (423,164) 175,208 Designated – Development 121,808 - - 121,808 Total unrestricted 278,966 441,214 (423,164) 297,016 Restricted The National Lottery Community Fund - RC England-wide 32,445 166,673 (158,322) 40,796 Male Cancer Nurse Information Specialist - other funders 8,252 12,100 (16,752) 3,600 The Innovation Research Project 92,800 68,700 (7,320) 154,180 Penile Cancer Peer Support - 8,500 (7,500) 1,000 Education and Awareness 5,000 58,950 (30,295) 33,655 Student Study and Travel Scholarships 6,729 - (2,000) 4,729 Roadshows 2,860 42,871 (38,871) 6,860 - Robert Lane Tissue Bank - 42,800 (42,800) - Young Person’s Testicular Cancer Project 3,228 - (3,228) - City of London Corporation 10,000 - (10,000) Total restricted 161,314 400,594 (317,088) 244,820 Total funds 440,280 841,808 (740,252) 541,836

Orchid Cancer Appeal | Annual report and nancial statements 2021-2022

14. Movements in funds (continued)

Prior year Brought forward Income Expenditure Carried forward £ £ £ £ Unrestricted General 135,382 250,731 (228,955) 157,158 Designated – Research 53,281 - (53,281) - Designated – Development 121,808 - - 121,808 Designated – Awareness 83,658 - (83,658) - Total unrestricted 394,129 250,731 (365,894) 278,966 Restricted Testicular Cancer Counselling - 3,000 (3,000) - The National Lottery Community Fund - RC England-wide - 89,497 (57,052) 32,445 Male Cancer Nurse Information Specialist - other funders 56,974 6,000 (54,722) 8,252 The Innovation Research Project 16,200 92,800 (16,200) 92,800 Penile Cancer Peer Support 5,000 2,500 (7,500) - Education and Awareness 11,250 23,050 (29,300) 5,000 Student Study and Travel Scholarships 6,729 - - 6,729 Roadshows 37,527 1,000 (35,667) 2,860 Robert Lane Tissue Bank - 57,700 (57,700) - Young Person’s Testicular Cancer Project 10,369 - (7,141) 3,228 National Lottery Community Fund – Covid 19 Emergency 37,328 - (37,328) - City of London Corporation 7,500 4,000 (1,500) 10,000 Total restricted 188,877 279,547 (307,110) 161,314 Total funds 583,006 530,278 (673,004) 440,280

General funds are unrestricted funds available for use at the Trustees’ discretion in furtherance of the general activities of the charity and which have not been designated for other purpose.

Designated Research funds represent monies set aside at the Trustees’ discretion to be used to help fund the costs of future research programmes.

Designated Development funds represent monies set aside at the Trustees’ discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

Designated Awareness funds represent monies set aside at the Trustees’ discretion to be used to help fund speci fi c awareness activities.

Welcome CEO’s letter The year in review Fundraising Our impact The year ahead Governance Financial review

15. Analysis of net assets between funds

Unrestricted Restricted Total funds at funds funds 30 September 2022 £ £ £ Fixed Assets 13,095 - 13,095 Current Assets 454,430 244,820 699,250 Creditors due within one year (170,509) - (170,509) Net assets at 30 September 2022 297,016 244,820 541,836 Prior year analysis of net assets between funds Fixed Assets 2,971 - 2,971 Current Assets 424,865 161,314 586,179 Creditors due within one year (148,870) - (148,870) Net assets at 30 September 2021 278,966 161,314 440,280

16. Related party transactions

Restricted donations of £52,500 were received from Professor RTD Oliver, trustee, in the year ended 30 September 2022. (Year to 30 September 2021: £80,000).

17. Financial commitments

For the year ended 30 September 2022, the charity was committed to making the following future payments under non cancellable operating leases.

Year ended Year ended 30 September 2022 30 September 2021 Total Total Land and buildings £ £ Expiring within one year 14,184 14,184 Expiring within two to fi ve years - - 14,184 14,184

18. Capital commitments

At the year ended 30 September 2022, the charity had capital commitments of £9,204 (2021: £Nil).

ORCHID FIGHTING MALE CANCER